CO-DEVELOPMENT RIGHTS (Details Narrative) - USD ($) |
3 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|
Mar. 31, 2025 |
Dec. 31, 2025 |
Dec. 31, 2021 |
Mar. 31, 2026 |
Sep. 30, 2021 |
Dec. 31, 2014 |
|
| CoDevelopmentLineItems [Line Items] | ||||||
| Outstanding principal balance | $ 218,750 | |||||
| License fees | $ 400,000 | |||||
| Co Development Rights [Member] | ||||||
| CoDevelopmentLineItems [Line Items] | ||||||
| Total gross capitalized co-development rights | $ 5,291,667 | |||||
| Accumulated amortization | $ 4,737,500 | 4,987,500 | ||||
| Net carrying amount | $ 554,167 | $ 304,167 | ||||
| Purple Bio Tech [Member] | ||||||
| CoDevelopmentLineItems [Line Items] | ||||||
| Outstanding principal balance | $ 218,750 | |||||
| Consensi Product [Member] | Purple Bio Tech [Member] | ||||||
| CoDevelopmentLineItems [Line Items] | ||||||
| Issuance of convertible debt | $ 1,500,000 | |||||
| CD38 Assets [Member] | Vy Gen [Member] | ||||||
| CoDevelopmentLineItems [Line Items] | ||||||
| Payments to Acquire Productive Assets | $ 1,750,000 | |||||
| Other Notes Payable, Noncurrent | 3,250,000 | |||||
| Total gross capitalized co-development rights | $ 5,000,000 | |||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Cash received from licensees for license fees during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|